Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 4/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 11/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487862 | 0.89 | CSNK2B (0.62) | CSNK2BCSNK2A2KCNH2TYK2CDK2 | |
| SCHEMBL12644933 | 0.84 | CSNK2A2 (0.47) | CSNK2BCSNK2A2KCNH2TYK2CDK2 | |
| SCHEMBL12841160 | 0.84 | CSNK2B (0.63) | CSNK2BCSNK2A2KCNH2TYK2CDK2 | |
| SCHEMBL12644938 | 0.82 | CSNK2A2 (0.45) | CSNK2BCSNK2A2KCNH2TYK2CDK2 | |
| SCHEMBL12583268 | 0.80 | CSNK2B (0.61) | CSNK2BCSNK2A2KCNH2CDK2MAPKAPK2 | |
| SCHEMBL12583256 | 0.80 | CSNK2B (0.61) | CSNK2BCSNK2A2KCNH2TYK2CDK2 | |
| SCHEMBL14158262 | 0.80 | CSNK2B (0.63) | CSNK2BCSNK2A2KCNH2TYK2CDK2 | |
| SCHEMBL2032405 | 0.79 | CSNK2B (0.68) | CSNK2BCSNK2A2KCNH2TYK2CDK2 | |
| SCHEMBL12583240 | 0.79 | CSNK2B (0.67) | CSNK2BCSNK2A2KCNH2CDK2MAPKAPK2 | |
| SCHEMBL2032956 | 0.78 | CSNK2B (0.63) | CSNK2BCSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | PIM2, PIM1, PIM3 | CSNK2B 17/4885CSNK2A2 9/4885KCNH2 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.